Login / Signup

RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL.

Adriano VendittiAlfonso PiciocchiAnna CandoniValentina ArenaRaffaele PalmieriCarla FiliAngelo Michele CarellaValeria CalafioreRoberto CairoliPaolo De FabritiisGabriella StortiPrassede SalutariFrancesco LanzaGiovanni MartinelliAntonio CurtiMario LuppiClaudia IngrossoMaria Paola MartelliAntonio CuneoFrancesco AlbanoAntonino MulèAgostino TafuriLaura CudilloAlessia TieghiNicola Stefano FracchiollaDebora CapelliSilvia Maria TrisoliniCaterina AlatiEdoardo La SalaLuca MaurilloMaria Ilaria Del PrincipeMaria Antonietta Irno ConsalvoMaria Domenica DivonaTiziana OttoneRaffaella CerrettiGiuseppe SconocchiaMaria Teresa Teresa VosoPaola FaziMarco VignettiFrancesco Buccisano
Published in: Blood advances (2024)
Keyphrases
  • acute myeloid leukemia
  • allogeneic hematopoietic stem cell transplantation
  • phase iii
  • study protocol
  • clinical trial
  • phase ii
  • acute lymphoblastic leukemia
  • open label